REGENXBIO Inc. (RGNX) has made remarkable progress in being able to advance its pipeline with various types of gene therapies. The last time I wrote about this article it was in a Seeking Alpha ...
Sarepta Therapeutics says its RNA therapy for Duchenne muscular dystrophy (DMD) could be more effective than its existing drugs, but a dose-escalation study also dug up some new—and serious—adverse ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular dystrophy at the front of the line. The company is positioning the program ...
Capricor Therapeutics, Inc. (CAPR) has a significant catalyst that is rapidly approaching, which could change the scope of this biotech. This would be regarding the release of top-line data from ...
Sarepta Therapeutics SRPT posted third-quarter 2024 adjusted earnings per share (EPS) of 62 cents, which beat the Zacks Consensus Estimate of a loss of 15 cents. Earnings rose 99% year over year, ...
Students are eligible to enter the DMD/MPH program after the second year of predoctoral studies in dentistry. The combined program will allow students who have demonstrated academic excellence to earn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results